FT819

DRUG3 trials

Sponsors

Fate Therapeutics

Conditions

Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)Chronic Lymphocytic LeukemiaIdiopathic Inflammatory Myositis (IIM)Lupus NephritisLupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IVLymphoma, B-CellPrecursor B-Cell Acute Lymphoblastic Leukemia

Phase 1

FT819 in Subjects With B-cell Malignancies

Active, not recruitingNCT04629729

Fate TherapeuticsChronic Lymphocytic Leukemia, Lymphoma, B-Cell, Precursor B-Cell Acute Lymphoblastic Leukemia

Start: 2021-07-12End: 2039-09-30Updated: 2026-03-19

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

RecruitingNCT06308978

Fate TherapeuticsAntineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Lupus Nephritis +2

Start: 2024-03-28End: 2042-09-30Target: 244Updated: 2026-05-22

Phase 2

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

RecruitingNCT07570862

Fate TherapeuticsLupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV +2

Start: 2026-07-27End: 2030-01-31Target: 53Updated: 2026-09-14

Related Papers

Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy

Blood2021-11-0510 citations